Luqa Pharma In-licenses Novel Wound Product from Histocell

Luqa Pharmaceuticals of Hong Kong expanded its dermatology portfolio by in-licensing greater China rights to Reoxcare, an IP-protected dressing for hard-to-heal skin wounds, from Histocell, a Spanish biopharma. Reoxare is intended for chronic skin ulcers and traumatic or surgical wounds. Luqa expects to launch Reoxcare in early 2015 in mainland China, Hong Kong and Macau, once it is approved. Financial details of the transaction were not disclosed. More details.... Share this with colleagues: // //